Ser656
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser656  -  PIMT (human)

Site Information
AQRYRLFsRFDDGIk   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 1881245402

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
liver cancer ( 1 )
Relevant cell line - cell type - tissue:
hepatocyte ( 1 ) , HepG2 (hepatic) ( 1 ) , liver ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKACA (human) ( 1 )
Kinases, in vitro:
PKACA (human) ( 1 )
Treatments:
8-Rp-cAMP ( 1 ) , fasting ( 1 ) , H-89 ( 1 ) , high-fat diet ( 1 ) , NKH_477 ( 1 )

Downstream Regulation
Effects of modification on PIMT:
molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 ) , transcription, altered ( 1 )
Induce interaction with:
p300 (human) ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
type 2 diabetes ( 1 )

References 

1

Kapadia B, et al. (2023) PIMT regulates hepatic gluconeogenesis in mice. iScience 26, 106120
36866247   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.